Neurological Surgery 脳神経外科39巻6号

2011年06月発行

研究

肺癌からの転移性脳腫瘍におけるEGFR遺伝子変異とgefitinibの有効性

著者： 小野恭裕¹ 豊田康則¹ 豊嶋敦彦¹ 蔵本智士¹ 勝間田篤¹ 河内正光¹ 松本祐蔵¹

所属機関： ¹香川県立中央病院脳神経外科

ページ範囲：P.569 - P.574

Ⅰ．はじめに

　肺癌からの脳転移の多くは，一部の腫瘍を除いて一般に化学療法が奏効しにくいため，最近まで手術摘出と放射線治療が主たる治療手段であった．最近，原発巣の非小細胞肺癌に対して上皮成長因子受容体（epidermal growth factor receptor：EGFR）遺伝子変異（以下，EGFR変異）をもつ症例に関してはEGFRチロシンキナーゼ阻害剤（tyrosine kinase inhibitor：TKI）の有効性が示唆されている^6,7,11)．今回，われわれは非小細胞肺癌の転移性脳腫瘍においてEGFR変異とEGFR-TKIの初期治療としての抗腫瘍効果について検討を行った．

参考文献

1）Clarke JL, Pao W, Wu N, Miller VA, Lassman AB：High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99：283-286, 2010

2）Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Janne PA：Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29：2346-2356, 2010

3）Japan clinical oncology group：National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 3.0, 2004) ─日本語訳JCOG版―第3版―. pp1-82（Japan clinical oncology group：National Cancer Institute-Common Toxicity Criteria, 東京, 2004）

4）Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T：Efficacy of erlotinib for brain and leptomeningeal metastasis in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4：1415-1419, 2009

5）Kim JE, Lee DH, Choi T, Yoon DH, Kim SW, Suh C, Lee JS：Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65：351-354, 2009

6）Lynch TJ, Bell DW, Sordella R, Gurubhagevatula S, Okimoto RA, Harris PL, Haserlat SM, Supuko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA：Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350：2129-2139, 2004

7）Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T：Gefitinib or chrmotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362：2380-2388, 2010

8）Mitudomi T, Yatabe Y：Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98：1817-1824, 2007

9）光冨徹哉：EGFRに対する小分子阻害剤．癌と化学療法36：1058-1062, 2009

10）日本肺癌学会編：日本肺癌学会肺癌診療ガイドラインStageⅣ未治療非小細胞肺癌．pp1-27（日本肺癌学会編：日本肺癌学会肺癌診療ガイドライン．東京，2010）

11）Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaya FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M：EGFR mutations in lung cancer：correlation with clinical response to gefitinib therapy. Science 304：1497-1500, 2004

12）Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M. for the Spanish Lung Cancer Group：Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361：958-967, 2009

13）Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J：EGFR mutations in patients with brain metastases from lung candcer：association with the efficacy of gefitinib. Neuro Oncol 8：137-144, 2006